New agents for the treatment of gout and hyperuricemia: Febuxostat, puricase, and beyond

Current Rheumatology Reports

Volumn 12, Issue 2, 2010, Pages 130-134

  Schlesinger, Naomi ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Gout; New agents; Treatment

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; CANAKINUMAB; COLCHICINE; FEBUXOSTAT; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PEGLOTICASE; PLACEBO; RASBURICASE; RDEA 594; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; URATE OXIDASE; Y 700;

ANAPHYLAXIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GOUT; HEMOLYSIS; HUMAN; HYPERURICEMIA; LOW DRUG DOSE; METHEMOGLOBINEMIA; RECOMMENDED DRUG DOSE; REVIEW;

ACUTE DISEASE; CHRONIC DISEASE; COLCHICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; POLYETHYLENE GLYCOLS; THIAZOLES; URATE OXIDASE;

EID: 77953478675     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0093-2     Document Type: Review

References (27)

1. Hench PS, Bauer W, Fletcher AA, et al.: Present status of the problem of "rheumatism": review of recent American and English literature on "rheumatism" and arthritis (part 3). Ann Intern Med 1935, 8:1673-1697.
2. Katzung BG: Basic and Clinical Pharmacology. Edited by Katzung BG. Norwalk, CT: Appleton and Lange; 1995:536-559.
3. Martinon F, Petrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
4. Terkeltaub B, Furst DE, Bennett K, et al.: Colchicine efficacy assessed by time to 50% reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the AGREE trial. Arthritis Rheum 2009, 59:S1108. This study highlights needed information about colchicine dosing in acute gout.
5. Colcrys.com: Highlights of prescribing information. Available at http://www.colcrys.com/assets/pdfCOLCRYS-Full-Prescribing-Information.pdf Accessed January 2010.
6. US Food and Drug Administration: Highlights of prescribing information: Colocrys. Available at www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 022351lbl.pdf. Accessed January 2010.
7. Di Giovine FS, Malawista SE, Nuki G, Duff GW: Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol 1987, 138:3213-3218.
8. Cronstein RN, Terkeltaub R: The inflammatory process of gout and its treatment. Arthritis Res Ther 2006, 8:S3.
9. So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007,12: R28. This important pilot study demonstrated that IL-1 blockade is helpful in the treatment of acute gout.
10. Terkeltaub R, Sundy JS, Schumacher HR et al.: The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study. Ann Rheum Dis 2009, 68:1613-1617.
11. So A, De Meulemeester M, Shamim T, et al.: Canakinumab (ACZ885) vs. triamcinolone actonide for treatment of acute gout in patients refractory or contraindicated to NSAIDs and/or colchicine. Late breaking abstract. Arthritis Rheum 2009, 60: LB4 p3660-1. This important large study in acute gout demonstrated that IL-1 blockade is helpful, especially compared with triamcinolone in the treatment of acute gout.
12. Schumacher HR, Sundy JS, Terkeltaub R, et al.: Placebo-controlled study of rilonacept for gout flare prophylaxis during initiation of urate-lowering therapy. Arthritis Rheum 2009, 59: S1096. This important study demonstrates the use of IL-1 blockade in gout prophylaxis.
13. Becker MA, Kisicki J, Khosravan R, et al.: Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004, 23:1111-1116.
14. Khosravan R, Grabowski BA, Mayer MD, et al.: The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2006, 46:88-102.
15. Hoshide S, Takahashi Y, Ishikawa T, et al.: PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate kidney disease (chronic kidney disease (CKD) stages 2 and 3). Nucleosides Nucleotides Nucleic Acids 2004, 23:1117-1118. This noteworthy study demonstrated the pharmacokinetics, pharmacodynamics, and safety of febuxostat in patients with CKD 2 and 3.
16. Becker MA, Schumacher HR Jr, Espinosa L, et al.: A phase 3 randomized, controlled, multicenter, double-blind trial comparing efficacy and safety of daily febuxostat and allopurinol in subjects with gout. Arthritis Rheum 2008, 58:4029-4029.
17. Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461.
18. Schumacher HR Jr, Becker MA, Lloyd E, et al.: Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology 2009, 48:188-194.
19. Varela-Echavarria A, Montes de Oca-Luna R, Barrera-Saldana HA: Uricase protein sequences: conserved during vertebrate evolution but absent in humans. The FASEB Journal 1988, 2:3092-3096.
20. Goldman SC, Holcenberg JS, Finklestein JZ, et al.: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97:2998-3003.
21. Moolenburgh JD, Reinders MK, Jansen TL: Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 2006, 25:749-752.
22. Richette P, Briere C, Hoenen-Clavert V, et al.: Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007, 34:2093-2098.
23. Sundy JS, Baraf HS, Becker MA, et al.: Efficacy and safety of intravenous (IV) pegloticase (PGL) in subjects with treatment failure gout (TFG): phase 3 results from GOUT1 and GOUT2. Arthritis Rheum 2008, 58:S635. This noteworthy study reviewed the use of pegloticase as urate-lowering therapy in patients with chronic severe gout.
24. Wright D, Sundy JS, Rosario-Jansen T: Routine serum uric acid (SUA) monitoring predicts antibody-mediated loss of response and infusion reaction risk during pegloticase therapy. Arthritis Rheum 2009, 59:S1104.
25. Maroli AN, Waltrip R, Alton M, et al.: First application of computer-assisted analysis of digital photographs for assessing tophus response: phase 3 studies of pegloticase in treatment failure gout. Arthritis Rheum 2009, 59:S1 111.
26. Bomalaski JS, Clark MA: Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheum Rep 2004, 6:240-247.
27. Ardea Biosciences: Development pipeline: gout. Available at http://www.ardeabio.com/gout.html. Accessed January 2010.